TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01841177

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milrinone
Description: Milrinone is a potent selective phosphodiesterase (PDE) type III inhibitor which stimulates myocardial function (inotropy), causes peripheral vasodilatation (afterload reduction) and improves myocardial relaxation (lusitropy).
Study: NCT03510715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Pharmaceutical form: tablet,~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin
Description: Pharmaceutical form: tablet,~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Pharmaceutical form: tablet,~Route of administration: oral
Study: NCT04406779

Intervention type: DEVICE
Intervention: thyroid USG was perform, blood samples were taken for the meausurement of thyroid hormone and autoantibodies
Description: thyroid USG was perform, blood samples were taken for the meausurement of thyroid hormone and autoantibodies

Intervention type: DEVICE
Intervention: thyroid USG was perform, blood samples were taken for the meausurement of thyroid hormone and autoantibodies
Description: thyroid USG was perform, blood samples were taken for the meausurement of thyroid hormone and autoantibodies
Study: NCT02029053

Intervention type: DEVICE
Group type: OTHER
Intervention: Vaginal Lubrication Ring for Vaginal Dryness
Description: Participants will be asked to complete 4 study visits and one final follow-up phone call. Each study visit will include a brief vaginal exam where vaginal fluid levels and pH levels are checked and questionnaires are completed. Daily diaries will be completed at home and returned to the study staff at subsequent visits.~Participants will self-insert the Intravaginal ring on the 1st study visit. The 2nd study visit will occur 3-4 days later.~The 3rd study visit will occur approximately 7 days after the 1st visit. Participants will remove the device and self-insert a new intravaginal ring.~The 4th study visit will occur approximately 14 days after the first visit. Participants will remove the intravaginal ring and undergo a final vaginal exam.~Participants will be called approximately 7 days after the last visit and will be asked about their current vaginal dryness symptoms and how they felt about the device during the study.
Study: NCT00867347

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Patients undergo radical cystectomy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo radiotherapy
Study: NCT01841177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milrinone
Description: Milrinone is a potent selective phosphodiesterase (PDE) type III inhibitor which stimulates myocardial function (inotropy), causes peripheral vasodilatation (afterload reduction) and improves myocardial relaxation (lusitropy).
Study: NCT04139473

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hepaticojejunostomy / Duct-to-duct anastomosis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hepaticojejunostomy / Duct-to-duct anastomosis
Study: NCT03995836

Intervention type: DEVICE
Intervention: CPAP
Description: Decision of CPAP treatment is according to clinical guidelines

Intervention type: PROCEDURE
Intervention: Bariatric Surgery
Description: All patients.

Intervention type: PROCEDURE
Intervention: Bariatric Surgery
Description: All patients.
Study: NCT00703196

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: folic acid
Description: Given orally once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally once daily
Study: NCT02969551

Intervention type: DEVICE
Intervention: Manometry and possibly DISE
Description: A Manometry is performed on all patients. After it in some Patient DISE is followed
Study: NCT01090973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: The LBH589 capsule(s) should be swallowed by mouth with a glass of water (8 ounces noncarbonated) in the morning. The daily dose of LBH589 should be taken at approximately the same time each day. Patients should avoid eating grapefruit, Seville (sour) orange or drinking grapefruit juice or Seville orange juice during the study.~After 2 cycles of treatment, if patients do not demonstrate a partial response or complete response (all of the tumor is gone) to the therapy they will be removed from the study. If patients do obtain a partial (the tumor(s) have decreased in size or number but there are still tumors present) or complete response then treatment will continue until their disease progresses.
Study: NCT04515446

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Rapid test for diagnosis orientation
Description: Rapid tests screen for influenza viruses in less than 30 minutes. They detect internal viral nucleoproteins by immunochromatography using specific antibodies attached to one or more strips.
Study: NCT03510715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Pharmaceutical form: tablet,~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Description: Pharmaceutical form: oral suspension,~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinic acid
Description: Pharmaceutical form: tablet,~Route of administration: oral
Study: NCT04515446

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: quantitative PCR
Description: Molecular biology method of gene amplification in vitro. It allows a large number of known DNA or RNA sequences to be duplicated
Study: NCT01848704

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: interpretation of the abstract

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interpretation of the abstract
Study: NCT01336192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1250mg/m\^2 Day 1 and 8, 28 days per cycle until PD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best supportive care
Description: Best supportive care
Study: NCT03510715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Pharmaceutical form: tablet,~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Description: Pharmaceutical form: capsule,~Route of administration: oral
Study: NCT05007158

Intervention type: OTHER
Intervention: procalcitonin blood test
Description: blood samples of all participants were analyzed for procalitonin levels, using a commercially available procalitonin testing kit
Study: NCT03366012

Intervention type: DEVICE
Group type: OTHER
Intervention: Cytosponge
Description: The Cytosponge consists of a 3cm diameter, polyester, medical grade spherical sponge on a string, compressed within a gelatin capsule. The capsule is swallowed while the patient or the research specialist holds onto the string. After 3-5 minutes the gelatin capsule dissolves allowing the spherical sponge to expand. The sponge is then retrieved by gently pulling on the string, thus collecting cells along the passageway through the entire length of the esophagus. The sample is then put into a preservative to be processed for immunohistochemical testing for trefoil factor 3 (TFF3) to determine diagnosis of Barrett's esophagus.
Study: NCT03989414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days
Study: NCT05007158

Intervention type: OTHER
Intervention: procalcitonin blood test
Description: blood samples of all participants were analyzed for procalitonin levels, using a commercially available procalitonin testing kit

Intervention type: OTHER
Intervention: procalcitonin blood test
Description: blood samples of all participants were analyzed for procalitonin levels, using a commercially available procalitonin testing kit

Intervention type: OTHER
Intervention: procalcitonin blood test
Description: blood samples of all participants were analyzed for procalitonin levels, using a commercially available procalitonin testing kit
Study: NCT03720808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balloon Blowing
Description: The parents of the children in this group were asked whether their children had the latex allergy or not and the children without the allergy were included in the group. The children's skills of blowing balloon were observed before the procedure. Before starting the venous blood sampling procedure, the children were asked to choose a balloon in the color they preferred and to start blowing the balloon at least 20 seconds before the procedure. Venous blood sampling started as the children exhaled to blow up the balloon. Until the venous blood procedure ended, they continued to blow up the balloons.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ball Squeezing
Description: Before the venous blood collecting procedure, a soft ball was given to the right hands of the children and they were asked to squeeze and release this ball during the procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coughing
Description: The children included in this group were asked to cough after taking a deep breath during the venous blood sampling procedure. Before the procedure, the researcher showed the children how they should cough and asked them to imitate. The venous blood sampling was not performed until the child successfully completed coughing. The child was directed by the researcher during the procedure. Just before the entrance of the needle, the child was asked to take a deep breath and the venous blood sampling procedure was started during coughing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: No intervention was performed to reduce pain and fear in the control group.
Study: NCT03989414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days
Study: NCT04670484

Intervention type: OTHER
Group type: OTHER
Intervention: Wearing Mask
Description: Participants wearing masks as per federal guidelines to prevent Coronavirus spread
Study: NCT03989414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days
Study: NCT03449576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trauma Management Therapy
Description: Trauma Management Therapy (TMT) consists of a combination of 12 sessions of individualized exposure therapy and 24 sessions of group-based social and emotion rehabilitation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exposure Therapy with Psychotherapy group
Description: Exposure Therapy with Psychoeducation (EXP+EDU) consists of a combination of 12 sessions of individualized exposure therapy and 24 session of group-based psychoeducation.
Study: NCT04411199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-PLEX
Description: D-PLEX is a new formulation of extended release of Doxycycline. Each 5g D-PLEX vial contains 54.6mg Doxycycline free base (1.09%), which is equivalent to 63mg Doxycycline hyclate (1.26%). D-PLEX is supplied as a sterile powder to be reconstituted to paste in the operating room, using standard aseptic techniques and is intended for single administration. The non-active components of the extended release antibiotic formulation are β Tri-Calcium polymer and a lipid matrix. All formulation components are biodegradable.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care (SoC)
Description: prophylactic, pre-operation per institution guidelines

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care (SoC)
Description: prophylactic, pre-operation per institution guidelines
Study: NCT03633201

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cruciate Retaining
Description: Zimmer Biomet's Personalized Knee system for knee osteoarthritis treatment. The standard insert.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medial Congruent
Description: Zimmer Biomet's Personalized Knee system for knee osteoarthritis treatment. The new anatomical congruent shaped insert.
Study: NCT04206787

Intervention type: DRUG
Intervention: Afatinib
Description: drug
Study: NCT03989414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days
Study: NCT03077061

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement
Description: Open flap debridement using saline as irrigation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open flap debridement
Description: Open flap debridement using saline as irrigation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone replacement graft
Description: Open flap debridement using saline as irrigation including a grafting procedure withBio-Oss Collagen®.
Study: NCT03830398

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: The investigators apply paracetamol during a week in preoperative room 45 min before ECT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deksketoprofen trometamol
Description: The investigators apply paracetamol during a week in preoperative room 45 min before ECT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The investigators apply placebo during a week in preoperative room 45 min before ECT
Study: NCT04799535

Intervention type: PROCEDURE
Intervention: Ultrasound
Description: Undergo breast ultrasound
Study: NCT00716079

Intervention type: OTHER
Group type: OTHER
Intervention: Blood pressure management policies
Description: The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood pressure management policies
Description: The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets.
Study: NCT00703482

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fenofibrate/CoQ10
Description: Fenofibrate pbo/CoQ10 placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate/CoQ10
Description: Fenofibrate pbo/CoQ10 200 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fenofibrate/CoQ10
Description: Fenofibrate 160mg/CoQ10 placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate/CoQ10
Description: Fenofibrate 160mg/CoQ10 placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate/CoQ10
Description: Fenofibrate 80/CoQ10 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate/CoQ10
Description: Fenofibrate 160mg/CoQ10 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate/CoQ10
Description: Fenofibrate 80 /CoQ10 200 mg
Study: NCT02288351

Intervention type: OTHER
Group type: OTHER
Intervention: labs
Description: Fasting Plasma Glucose (FPG) and insulin will be added to the standard pre-operative labs.

Intervention type: OTHER
Group type: OTHER
Intervention: Biopsy
Description: Intra-operatively: Subjects will undergo a standard laparoscopic Roux-en-Y Gastric Bypass (RYGB). During the surgery a 2cm tissue sample of the Roux limb will be taken by the doctor and frozen.
Study: NCT00703482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate/CoQ10
Description: Fenofibrate 160mg/CoQ10 200 mg
Study: NCT03097211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules. Orally, with 240 mL of potable water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules. Orally, with 240 mL of potable water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules. Orally, with 240 mL of potable water.
Study: NCT02637791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual glove
Description: The intervention (the virtual glove) consists of a hand-mounted power unit, with four infra- red light emitting diodes (LEDs) mounted on the user's finger tips. The LEDs are tracked using one or two Nintendo Wii motes mounted by the computer screen on which the games are displayed to translate the location of the user's hand, fingers and thumb in 3D space. Three games have been produced especially for the project with the help of therapists and stroke patients. In order to play them, users have to perform the movements of reach to grasp, grasp and release, pronation and supination that are necessary to effect many activities of daily living.
Study: NCT05344079

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 18-Gauge Touhy (Egemen®, Combifix Standard Spinal Epidural Combined Set, İzmir, Turkey)
Description: Patients in this group were entered the epidural space from the midline using the loss of resistance method with an 18-Gauge Touhy (Egemen®, Combifix Standard Spinal Epidural Combined Set, İzmir, Turkey) needle from the L4-L5 or L5-S1 vertebral space. After the free cerebrospinal fluid flow is observed by passing the spinal needle through the epidural needle, spinal anaesthesia was maintained with 10-15 mg hyperbaric bupivacaine (Bustesin®, 0.5% Spinal Heavy Vem Pharmaceuticals, Turkey). After the epidural catheter was fixed in such a way that it remained 5 cm in the epidural space, the adapter was inserted and fixed. Whether the catheter is in place or not was checked by 2 mL (40 mg) Lidocaine (Aritmal®, 2% 100 mg/5 mL amp., Biosel, Turkey) + 1/2000000 adrenaline test dose.
Study: NCT03097211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules. Orally, with 240 mL of potable water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512
Description: The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 75 mg, 100 mg. Orally, with 240 mL of potable water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512
Description: The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 75 mg, 100 mg. Orally, with 240 mL of potable water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512
Description: The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 75 mg, 100 mg. Orally, with 240 mL of potable water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512
Description: The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 75 mg, 100 mg. Orally, with 240 mL of potable water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Madopar® 250
Description: Levodopa/benserazide immediate release tablets 200mg/50mg. Orally, with 240 mL of potable water.
Study: NCT02288351

Intervention type: OTHER
Group type: OTHER
Intervention: Second Mix Nutrient Meal
Description: 2 months post-operatively a second mixed nutrient stimulation test will be performed following the same process used pre-operatively.
Study: NCT03097211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Madopar® 250
Description: Levodopa/benserazide immediate release tablets 200mg/50mg. Orally, with 240 mL of potable water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Madopar® 250
Description: Levodopa/benserazide immediate release tablets 200mg/50mg. Orally, with 240 mL of potable water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Madopar® 250
Description: Levodopa/benserazide immediate release tablets 200mg/50mg. Orally, with 240 mL of potable water.
Study: NCT02288351

Intervention type: OTHER
Group type: OTHER
Intervention: Second biopsy
Description: . Patients will also be scheduled to undergo a second upper endoscopy and a 2cm biopsy of the Roux limb will be taken by the doctor and frozen in liquid nitrogen.
Study: NCT03097211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebicapone
Description: Nebicapone 150 mg tablets. Orally, with 240 mL of potable water.
Study: NCT02288351

Intervention type: DEVICE
Group type: OTHER
Intervention: PET/CT
Description: Lastly, subjects will have a positron emission tomography/computed tomography (PET/CT) scan with Fluorodeoxyglucose (FDG) to evaluate the glucose in the Roux limb after surgery.